

|  |
| --- |
| **Европейски формат на автобиография** |

|  |
| --- |
| **Лична информация** |

|  |  |  |
| --- | --- | --- |
| Име |  | **Дарина Людмилова Качакова-Йорданова** |
|  |  |  |
|  |  |  |
|  |  |  |
| E-mail |  | [**darina.kachakova@gmail.com**](mailto:darina.kachakova@gmail.com)**, darina\_kachakova@mmcbg.org** |

|  |  |  |
| --- | --- | --- |
| Националност |  | Българска |

|  |  |  |
| --- | --- | --- |
| Дата на раждане |  | 17.12.1984 |

|  |
| --- |
| **Трудов стаж** |

|  |  |  |
| --- | --- | --- |
| **•** Дати (от-до) |  | **Март 2013 до момента** |
| **•** Име и адрес на работодателя |  | Лаборатория по геномна диагностика, Център по молекулна медицина, катедра Медицинска химия и биохимия, Медицински факултет, Медицински университет - София |
| **•** Вид на дейността или сферата на работа |  | Генетични анализи |
| **•** Заемана длъжност |  | **Биолог-генетик** |
| **•** Основни дейности и отговорности |  | Планиране и провеждане на научно-изследователски и експерименти и анализи, интерпретация на получени генетични резултати. Усъвършенстване или разработване на лабораторни методи. Кандидатстване в конкурси за финансиране на научно-изследователски проекти. Провеждане на анализи за определяне на генетичната причина за възникване на редица заболявания. |
| • Дати (от-до) |  | **Март 2010 до Март 2013** |
| • Име и адрес на работодателя |  | Лаборатория по геномна диагностика, Център по молекулна медицина, катедра Медицинска химия и биохимия, Медицински факултет, Медицински университет - София |
| • Вид на дейността или сферата на работа |  | Генетични анализи |
| • Заемана длъжност |  | **Докторант** зачислен със Заповед №Р.185/15.03.2010 |
| • Основни дейности и отговорности |  | Провеждане на генетични, епигенетични, експресионни анализи при рака на простатата . |

|  |  |  |
| --- | --- | --- |
| • Дати (от-до) |  | **Юни 2009- до март 2010** |
| • Име и адрес на работодателя |  | Лаборатория по геномна диагностика, Център по молекулна медицина, катедра Медицинска химия и биохимия, Медицински факултет, Медицински университет - София |
| • Вид на дейността или сферата на работа |  |  |
| • Заемана длъжност |  | **Биолог-лаборант** |
| • Основни дейности и отговорности |  | Изолиране на високомолекулна ДНК и РНК. Участие в генетични анализи |

|  |  |  |
| --- | --- | --- |
| • Дати (от-до) |  | **Март 2009- до май 2009** |
| • Име и адрес на работодателя |  | Национална генетична лаборатория, София |
| • Вид на дейността или сферата на работа |  |  |
| • Заемана длъжност |  | **медицински-лаборант** |
| • Основни дейности и отговорности |  | Изолиране на високомолекулна ДНК от венозна кръв, амниотична течност, хорионни въси, абортивен материал. |

|  |
| --- |
| **Образование и обучение** |

|  |  |  |  |
| --- | --- | --- | --- |
| • Дати (от-до) |  | 2003 г-2007г. | ] |
| • Име и вид на обучаващата или образователната организация |  | Софийски университет „Св. Климент Охридски” |  |
| • Основни предмети/застъпени професионални умения |  | Специалност Молекулярна биология |  |
| • Наименование на придобитата квалификация |  | Бакалавър |  |
|  |  |  |  |
| • Дати (от-до) |  | 2007 г-2009г. | |
| • Име и вид на обучаващата или образователната организация |  | Софийски университет „Св. Климент Охридски” | |
| • Основни предмети/застъпени професионални умения |  | Специалност Генетика | |
| • Наименование на придобитата квалификация |  | Магистър | |
| • Дати (от-до) |  | 15.03.2010 до 2013г. | |
| • Име и вид на обучаващата или образователната организация |  | Медицински Университет – София, катедра Медицинска химия и биохимия | |
| • Основни предмети/застъпени професионални умения |  | Научна специалност Молекулярна генетика | |
| • Наименование на придобитата квалификация |  | Доктор на науките, придобита на 01.06.2015, дисертация „Молекулно профилиране при рака на простатата“ | |

**Обучения:**

2008г.- Курс по Биоетика, Перуджа, Италия

Camara D., Dimitrova Ir., Doynova M., Jachacz L., Kachakova D., Kepka M., Ould Isselmou CB., Vorniere JP., Yungarva Tsv. Transgenic and cloned animals: Ethical Problems? pdfs.semanticscholar.org

11.09.2008 - Курс на обучение за работа със система за лазерна микродисекция PALM MicroBeam LMD, Carl Zeizz, Германия, ръководен от представител на фирмата Carl Zeizz д-р Волф-Дитер Шулц, Германия, проведен в Център по молекулна медицина, катедра „Медицинска химия и биохимия”, Медицински Университет – София

1 - 5.11. 2010- Курс “Biomek Continuum - Basic Training” за оператори на автоматизирана роботизирана система Biomek, Нион, Швейцария, организиран от Фирмата производител, Beckman, Медицински Университет – София, катедра „Медицинска химия и биохимия”,

7 - 9.03.2011 - Специализиран курс за обучени по молекулна патология на рака: 1st EACR-OECI Joint Training Course “Molecular pathology Approach to cancer”, Амстердам

4-7.07.2011 - Специализирано обучение за работа със система за лазерна микродисекция PALM MicroBeam LMD, Carl Zeizz, Германия и приложението й при анализ на тумори, клетки и цитогенетични препарати, проведено от представител на фирмата Carl Zeizz д-р Кърстийн Хаден-Ман, Център по молекулна медицина

25-27.10.2011 - Биоинформатичен курс за работа с публичната база данни ENSEMBL и публични данни за: Анализ на нуклеотидни последоватености - Nucleotide Sequence databases; Транскриптомика и атлас на генната експресия - ArrayExpress & Gene Expression Atlas; Мас спектрометрия и протеомика - Mass Spectrometry based Proteomics, PRIDE и програми като BioMart за анализ на бази данни и извличане на информация („data mining”).

Организатори: Центъра по молекулна медицина, и Геномния център на СУ „Св. Климент Охридски”, съвместно с Европейския биоинформатичен институт EMBL (European Bioinformatics Institute). Гостуващи лектори от EMBL бяха Яна Вандровкова, Джеймс Уотсън, Емма Хестингс и Хуан Визкеино.

28-30.04.2014- Обучение за работа с микроРНК микрочипове и със специализиран софтуер GeneSpring за анализ на данни от микрочипове, организирано от Agilent Technologies, Inc, д-р Андреас Полтън, Валдброн, Германия

|  |
| --- |
| **Лични умения и компетенции**  *Придобити в жизнения път или в професията, но не непременно удостоверени с официален документ или диплома.* |

|  |  |  |
| --- | --- | --- |
| Майчин език |  | **Български** |

|  |
| --- |
| Други езици |

|  |  |  |
| --- | --- | --- |
|  |  | **Английски език** |
| **•** Четене |  | Отлично |
| **•** Писане |  | Добро |
| **•** Разговор |  | Добро |

|  |  |  |
| --- | --- | --- |
| умения и компетенции  *Съвместно съжителство с други хора в интеркултурно обкръжение, в ситуации, в които комуникацията и екипната работа са от съществено значение (например в културата и спорта) и др.* |  | Изолиране на ДНК и РНК от различни биологични материали, анализ на ДНК/РНК на агарозен гел, PCR технологии, Real time PCR, RFLP, SSCP, Фрагментен анализ, Директно секвениране, Новогенерационно секвениране, анализ и интерпретация на резултати от новогенерационно секвениране, Генна експресия, Микрочипов анализ, Работа с автоматизирана роботизирана система Biomek, Работа с със система за лазерна микродисекция PALM MicroBeam LMD, Асоциативни проучвания и статистика, Работа с бази дании |

|  |  |  |
| --- | --- | --- |
| Свидетелство за управление на МПС |  | Свидетелство за управление на МПС категория В и М |

|  |  |  |
| --- | --- | --- |
| **Допълнителна информация** |  | Препоръки ще бъдат предоставени при поискване.  Лица и/или организации, които могат да дадат професионална препоръка или отзив:  1. Проф. Алексей Савов, катедра „Акушерство и гинекология”, Медицински факултет, МУ  2. Проф. д-р Радка Кънева, катедра „Биохимия и химия”, Медицински факултет, МУ |

|  |  |  |
| --- | --- | --- |
| **Приложения** |  | Списък на научните публикации  Копие от трудовата книжка  Медицинско свидетелство  Свидетелство за съдимост  Нотариално заверена диплома за магистър |

Приложение 1

Списък на научните публикации на Дарина Качакова

1. Eeles RA, Kote-JaraiZ, Olama AA, .KanevaR, Slavov C, Mitkova A, Kachakova D…, The UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons’ Section of Oncology, The UK ProtecT Study Collaborators, The PRACTICAL Consortium, EastonDF, Identification of seven novel prostate cancer susceptibility loci through a genome-wide association stud*y*, Nature Genetics 2009, Oct;41(10):1116-21., october 2009; IF 2009 (34.284)

2. Kote-Jarai, Sofía, Ali Amin Al Olama, Graham G. Danielle M. Karyadi... Mitev...The **PRACTICAL** Consortium… (Kachakova D)…., Douglas F Easton, Rosalind A Eeles. The Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet. 2011 Jul 10. doi: 10.1038/ng.882. PubMed PMID: 21743467; ИФ 2011 (22.84)

3. Amin Al Olama A, Kote-Jarai Z, Schumacher FR, Wiklund F, Berndt SI, Benlloch S, Giles GG, ………Cybulski C, Lubinski J, Thibodeau SN, Schaid DJ, Sorensen KD, Batra J, Clements JA, Chambers S, Aitken J, Gardiner RA, Maier C, Vogel W, Dörk T, Brenner H, Habuchi T, Ingles S, John EM, Dickinson JL, Cannon-Albright L, Teixeira MR, Kaneva R, Zhang HW, Lu YJ, Park JY, Cooney KA, Muir KR, Leongamornlert DA, Saunders E, Tymrakiewicz M, Mahmud N, Guy M, Govindasami K, O'Brien LT, ……… Lose F, McDonnell SK, Joshi AD, Shahabi A, Pinto P, Santos J, Ray A, Sellers TA, Lin HY, Stephenson RA, Teerlink C, Muller H, Rothenbacher D, Tsuchiya N, Narita S, Cao GW, Slavov C, Mitev V; The UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; The UK ProtecT Study Collaborators; The Australian Prostate Cancer Bioresource; The **PRACTICAL** Consortium (…, Kachakova D, Mitkova A, Goranova T, Stancheva G,….), Chanock S, Gronberg H, Haiman CA, Kraft P, Easton DF, Eeles RA. [A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease.](http://www.ncbi.nlm.nih.gov/pubmed/23065704) Hum Mol Genet. 2013 Jan 15;22(2):408-15; PMID: IF 2013 (6.677)

4. Giles GG, Severi G, Wiklund F, Gronberg H, Haiman CA, Schumacher F, Henderson BE, Le Marchand L, Lindstrom S, Kraft P, Hunter DJ, Gapstur S, Chanock S, Berndt SI, Albanes D, Andriole G, Schleutker J, Weischer M, Canzian F, Riboli E, Key TJ, Travis RC, Campa D, Ingles SA, John EM, Hayes RB, Pharoah P, Khaw KT, Stanford JL, Ostrander EA, Signorello LB, Thibodeau SN, Schaid D, Maier C, Vogel W, Kibel AS, Cybulski C, Lubinski J, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Spurdle A, Clements JA, Teixeira MR, Govindasami K, Guy M, Wilkinson RA, Sawyer EJ, Morgan A, Dicks E, Baynes C, Conroy D, Bojesen SE, Kaaks R, Vincent D, Bacot F, Tessier DC; COGS-CRUK GWAS-ELLIPSE (Part of GAME-ON) Initiative; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators; **PRACTICAL** Consortium, Easton DF, Eeles RA. (2013) Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. Hum Mol Genet. 2013 Jun 15;22(12):2520-8. IF 2013 (6.677)

**5. Kachakova** D, Mitkova A, Popov E, Beltcheva O, Vlahova A, Dikov T, Hristova S, Mitev V, Slavov C, **Kaneva R**. [Evaluation of the clinical value of the newly identified urine biomarker HIST1H4K for diagnosis and prognosis of prostate cancer in Bulgarian patients](http://www.ncbi.nlm.nih.gov/pubmed/24065480). J BUON. 2013 Jul-Sep;18(3):660-8. IF 2013 (0.706)

6. Popov TM, Stancheva I, **Kachakova** DL, Rangachev J, Konov D, Varbanova S, Mitev VI, **Kaneva RP**, Popova DP. [Auditory Outcome After Cochlear Implantation in Patients With Congenital Nonsyndromic Hearing Loss: Influence of the GJB2 Status.](http://www.ncbi.nlm.nih.gov/pubmed/24691507) [Otol Neurotol.](http://www.ncbi.nlm.nih.gov/pubmed/24691507) 2014 Sep;35(8):1361-5, IF 2014 (1.598)

7. **Д. Качакова**, А. Миткова, Радка Кънева, Ваньо Митев. Ракът на простатата- генетично, геномно и епигенетично заболяване. Биоамаркери. Studia Oncologica,Октомври 2014, година VI, брой 3

8. Marinova, D., Slavova, Y., **Kachakova, D**., Stancheva, G., Mitkova, A., Kaneva, R., ... & Mitev, V. (2014). Gene expression of EGFR, MINA53, MEN1 and MTOR in NSCLCs. European Respiratory Journal, 44(Suppl 58), P2709.

**9. Kachakova** D, Mitkova A, Popov E, Popov I, Vlahova A, Dikov T, Christova S, Mitev V, Slavov C, Kaneva R. Combinations of Serum Prostate-Specific Antigen and Plasma Expression Levels of let-7c, miR-30c, miR-141, and miR-375 as Potential Better Diagnostic Biomarkers for Prostate Cancer. DNA Cell Biol. 2015 Mar;34(3):189-200, IF 2015 (2.574)

10. Kote-Jarai Z, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Dadaev T, Jugurnauth-Little S, Ross-Adams H, Al Olama AA, Benlloch S, Halim S, Russell R, Dunning AM, Luccarini C, Dennis J, Neal DE, Hamdy FC, Donovan JL, Muir K, Giles GG, Severi G, Wiklund F, Gronberg H, Haiman CA, Schumacher F, Henderson BE, Le Marchand L, Lindstrom S, Kraft P, Hunter DJ, Gapstur S, Chanock S, Berndt SI, Albanes D, Andriole G, Schleutker J, Weischer M, Canzian F, Riboli E, Key TJ, Travis RC, Campa D, Ingles SA, John EM, Hayes RB, Pharoah P, Khaw KT, Stanford JL, Ostrander EA, Signorello LB, Thibodeau SN, Schaid D, Maier C, Vogel W, Kibel AS, Cybulski C, Lubinski J, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Spurdle A, Clements JA, Teixeira MR, Govindasami K, Guy M, Wilkinson RA, Sawyer EJ, Morgan A, Dicks E, Baynes C, Conroy D, Bojesen SE, Kaaks R, Vincent D, Bacot F, Tessier DC; COGS-CRUK GWAS-ELLIPSE (Part of GAME-ON) Initiative; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators; **PRACTICAL** Consortium, Easton DF, Eeles RA. (2013) Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. Hum Mol Genet. 2013 Jun 15;22(12):2520-8. IF 2013 (6.677)

11. Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Ghoussaini M, Luccarini C, Dennis J, Jugurnauth-Little S, Dadaev T, Neal DE,Hamdy FC, Donovan JL, Muir K, Giles GG, Severi G, Wiklund F, Gronberg H, HaimanCA, Schumacher F, Henderson BE, Le Marchand L, Lindstrom S, Kraft P, Hunter DJ,Gapstur S, Chanock SJ, Berndt SI, Albanes D, Andriole G, Schleutker J, WeischerM, Canzian F, Riboli E, Key TJ, Travis RC, Campa D, Ingles SA, John EM, Hayes RB,Pharoah PD, Pashayan N, Khaw KT, Stanford JL, Ostrander EA, Signorello LB,Thibodeau SN, Schaid D, Maier C, Vogel W, Kibel AS, Cybulski C, Lubinski J,Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Spurdle AB, ClementsJA, Teixeira MR, Dicks E, Lee A, Dunning AM, Baynes C, Conroy D, Maranian MJ,Ahmed S, Govindasami K, Guy M, Wilkinson RA, Sawyer EJ, Morgan A, Dearnaley DP,Horwich A, Huddart RA, Khoo VS, Parker CC, Van As NJ, Woodhouse CJ, Thompson A,Dudderidge T, Ogden C, Cooper CS, Lophatananon A, Cox A, Southey MC, Hopper JL,English DR, Aly M, Adolfsson J, Xu J, Zheng SL, Yeager M, Kaaks R, Diver WR,Gaudet MM, Stern MC, Corral R, Joshi AD, Shahabi A, Wahlfors T, Tammela TL,Auvinen A, Virtamo J, Klarskov P, Nordestgaard BG, Røder MA, Nielsen SF, Bojesen SE, Siddiq A, Fitzgerald LM, Kolb S, Kwon EM, Karyadi DM, Blot WJ, Zheng W, CaiQ, McDonnell SK, Rinckleb AE, Drake B, Colditz G, Wokolorczyk D, Stephenson RA,Teerlink C, Muller H, Rothenbacher D, Sellers TA, Lin HY, Slavov C, Mitev V, LoseF, Srinivasan S, Maia S, Paulo P, Lange E, Cooney KA, Antoniou AC, Vincent D,Bacot F, Tessier DC; COGS–Cancer Research UK GWAS–ELLIPSE (part of GAME-ON)Initiative; Australian Prostate Cancer Bioresource; UK Genetic Prostate CancerStudy Collaborators/British Association of Urological Surgeons' Section ofOncology; UK ProtecT (Prostate testing for cancer and Treatment) StudyCollaborators; **PRACTICAL** (Prostate Cancer Association Group to InvestigateCancer-Associated Alterations in the Genome) Consortium, Kote-Jarai Z, Easton DF.Identification of 23 new prostate cancer susceptibility loci using the iCOGScustom genotyping array. Nat Genet. 2013 Apr;45(4):385-91, 391e1-2. doi:10.1038/ng.2560. PubMed PMID: 23535732; PubMed Central PMCID: PMC3832790. IF 2013 (29.648)

12. Al Olama AA, Kote-Jarai Z, Berndt SI, Conti DV, Schumacher F, Han Y, Benlloch S, Hazelett DJ, Wang Z, Saunders E, Leongamornlert D, Lindstrom S, Jugurnauth-Little S, Dadaev T, Tymrakiewicz M, Stram DO, Rand K, Wan P, Stram A, Sheng X, Pooler LC, Park K, Xia L, Tyrer J, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Yeager M, Burdette L, Chung CC, Hutchinson A, Yu K, Goh C, Ahmed M, Govindasami K, Guy M, Tammela TL, Auvinen A, Wahlfors T, Schleutker J, Visakorpi T, Leinonen KA, Xu J, Aly M, Donovan J, Travis RC, Key TJ, Siddiq A, Canzian F, Khaw KT, Takahashi A, Kubo M, Pharoah P, Pashayan N, Weischer M, Nordestgaard BG, Nielsen SF, Klarskov P, Røder MA, Iversen P, Thibodeau SN, McDonnell SK, Schaid DJ, Stanford JL, Kolb S, Holt S, Knudsen B, Coll AH, Gapstur SM, Diver WR, Stevens VL, Maier C, Luedeke M, Herkommer K, Rinckleb AE, Strom SS, Pettaway C, Yeboah ED, Tettey Y, Biritwum RB, Adjei AA, Tay E, Truelove A, Niwa S, Chokkalingam AP, Cannon-Albright L, Cybulski C, Wokołorczyk D, Kluźniak W, Park J, Sellers T, Lin HY, Isaacs WB, Partin AW, Brenner H, Dieffenbach AK, Stegmaier C, Chen C, Giovannucci EL, Ma J, Stampfer M, Penney KL, Mucci L, John EM, Ingles SA, Kittles RA, Murphy AB, Pandha H, Michael A, Kierzek AM, Blot W, Signorello LB, Zheng W, Albanes D, Virtamo J, Weinstein S, Nemesure B, Carpten J, Leske C, Wu SY, Hennis A, Kibel AS, Rybicki BA, Neslund-Dudas C, Hsing AW, Chu L, Goodman PJ, Klein EA, Zheng SL, Batra J, Clements J, Spurdle A, Teixeira MR, Paulo P, Maia S, Slavov C, Kaneva R, Mitev V, Witte JS, Casey G, Gillanders EM, Seminara D, Riboli E, Hamdy FC, Coetzee GA, Li Q, Freedman ML, Hunter DJ, Muir K, Gronberg H, Neal DE, Southey M, Giles GG, Severi G; Breast and Prostate Cancer Cohort Consortium (BPC3); **PRACTICAL** (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; COGS (Collaborative Oncological Gene-environment Study) Consortium; GAME-ON/ELLIPSE Consortium, Cook MB, Nakagawa H, Wiklund F, Kraft P, Chanock SJ, Henderson BE, Easton DF, Eeles RA, Haiman CA. A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet. 2014 Oct;46(10):1103-9. doi: 10.1038/ng.3094. Epub 2014 Sep 14, IF 2014 (29.648)

13. Yu OH, Foulkes WD, Dastani Z, Martin RM, Eeles R; **PRACTICAL** Consortium; CRUK GWAS Investigators, Richards JB. An assessment of the shared allelic architecture between type II diabetes and prostate cancer. Cancer Epidemiol Biomarkers Prev.2013 Aug;22(8):1473-5. doi: 10.1158/1055-9965.EPI-13-0476. Epub 2013 May 23.PubMed PMID: 23704474 IF 2013 (4.324)

14. Shen H, Fridley BL, Song H, Lawrenson K, Cunningham JM, Ramus SJ, Cicek MS, Tyrer J, Stram D, Larson MC, Köbel M; **PRACTICAL** Consortium, Ziogas A, Zheng W, Yang HP, Wu AH, Wozniak EL, Woo YL, Winterhoff B, Wik E, Whittemore AS, Wentzensen N, Weber RP, Vitonis AF, Vincent D, Vierkant RA, Vergote I, Van Den Berg D, Van Altena AM, Tworoger SS, Thompson PJ, Tessier DC, Terry KL, Teo SH, Templeman C, Stram DO, Southey MC, Sieh W, Siddiqui N, Shvetsov YB, Shu XO, Shridhar V, Wang-Gohrke S, Severi G, Schwaab I, Salvesen HB, Rzepecka IK, Runnebaum IB, Rossing MA, Rodriguez-Rodriguez L, Risch HA, Renner SP, Poole EM, Pike MC, Phelan CM, Pelttari LM, Pejovic T, Paul J, Orlow I, Omar SZ, Olson SH, Odunsi K, Nickels S, Nevanlinna H, Ness RB, Narod SA, Nakanishi T, Moysich KB, Monteiro AN, Moes-Sosnowska J, Modugno F, Menon U, McLaughlin JR, McGuire V, Matsuo K, Adenan NA, Massuger LF, Lurie G, Lundvall L, Lubiński J, Lissowska J, Levine DA, Leminen A, Lee AW, Le ND, Lambrechts S, Lambrechts D, Kupryjanczyk J, Krakstad C, Konecny GE, Kjaer SK, Kiemeney LA, Kelemen LE, Keeney GL, Karlan BY, Karevan R, Kalli KR, Kajiyama H, Ji BT, Jensen A, Jakubowska A, Iversen E, Hosono S, Høgdall CK, Høgdall E, Hoatlin M, Hillemanns P, Heitz F, Hein R, Harter P, Halle MK, Hall P, Gronwald J, Gore M, Goodman MT, Giles GG, Gentry-Maharaj A, Garcia-Closas M, Flanagan JM, Fasching PA, Ekici AB, Edwards R, Eccles D, Easton DF, Dürst M, du Bois A, Dörk T, Doherty JA, Despierre E, Dansonka-Mieszkowska A, Cybulski C, Cramer DW, Cook LS, Chen X, Charbonneau B, Chang-Claude J, Campbell I, Butzow R, Bunker CH, Brueggmann D, Brown R, Brooks-Wilson A, Brinton LA, Bogdanova N, Block MS, Benjamin E, Beesley J, Beckmann MW, Bandera EV, Baglietto L, Bacot F, Armasu SM, Antonenkova N, Anton-Culver H, Aben KK, Liang D, Wu X, Lu K, Hildebrandt MA; Australian Ovarian Cancer Study Group; Australian Cancer Study, Schildkraut JM, Sellers TA, Huntsman D, Berchuck A, Chenevix-Trench G, Gayther SA, Pharoah PD, Laird PW, Goode EL, Pearce CL. Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun. 2013;4:1628. doi: 10.1038/ncomms2629. IF 2013 (10.742)

15. Laitinen VH, Rantapero T, Fischer D, Vuorinen EM, Tammela TL; **PRACTICAL Consortium**, Wahlfors T, Schleutker J. Fine-mapping the 2q37 and 17q11.2-q22 loci for novel genes and sequence variants associated with a genetic predisposition to prostate cancer. Int J Cancer. 2015 May 15;136(10):2316-27, IF 2015 (5.531)

16. Panagiotou OA, Travis RC, Campa D, Berndt SI, Lindstrom S, Kraft P, Schumacher FR, Siddiq A, Papatheodorou SI, Stanford JL, Albanes D, Virtamo J, Weinstein SJ, Diver WR, Gapstur SM, Stevens VL, Boeing H, Bueno-de-Mesquita HB, Gurrea AB, Kaaks R, Khaw KT, Krogh V, Overvad K, Riboli E, Trichopoulos D, Giovannucci E, Stampfer M, Haiman C, Henderson B, Le Marchand L, Gaziano JM, Hunter DJ, Koutros S, Yeager M, Hoover RN; The **PRACTICAL Consortium**, Chanock SJ, Wacholder S, Key TJ, Tsilidis KK. A Genome-wide Pleiotropy Scan for Prostate Cancer Risk. Eur Urol. 2015 Apr;67(4):649-57. doi: 10.1016/j.eururo.2014.09.020. [Epub ahead of print]; IF 2015 (14.976)

17. Han Y, Signorello LB, Strom SS, Kittles RA, Rybicki BA, Stanford JL, Goodman PJ, Berndt SI, Carpten J, Casey G, Chu L, Conti DV, Rand KA, Diver WR, Hennis AJ, John EM, Kibel AS, Klein EA, Kolb S, Le Marchand L, Leske MC, Murphy AB, Neslund-Dudas C, Park JY, Pettaway C, Rebbeck TR, Gapstur SM, Zheng SL, Wu SY, Witte JS, Xu J, Isaacs W, Ingles SA, Hsing A; **PRACTICAL** Consortium; ELLIPSE GAME-ON Consortium, Easton DF, Eeles RA, Schumacher FR, Chanock S, Nemesure B, Blot WJ, Stram DO, Henderson BE, Haiman CA. Generalizability of established prostate cancer risk variants in men of African ancestry. Int J Cancer. 2015 Mar 1;136(5):1210-7. doi: 10.1002/ijc.29066. Epub 2014 Jul 15. IF 2015 (5.531)

18. Andreassen OA, Zuber V, Thompson WK, Schork AJ, Bettella F; **PRACTICAL Consortium**; CRUK GWAS, Djurovic S, Desikan RS, Mills IG, Dale AM. Shared common variants in prostate cancer and blood lipids. Int J Epidemiol. 2014 Aug;43(4):1205-14. doi: 10.1093/ije/dyu090. Epub 2014 Apr 30. IF 2014 (9.197)

Marinova, D. M., Slavova, Y., Stancheva, G., **Kachakova, D**., Mitkova, A., & Kaneva, R. (2014, April). GENE EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTOR, MYC-INDUCED NUCLEAR ANTIGEN, 53KDA AND MECHANISTIC TARGET OF RAPAMYCIN IN PULMONARY NEUROENDOCRINE TUMORS. In JOURNAL OF THORACIC ONCOLOGY (Vol. 9, No. 4, pp. S10-S10). 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA: LIPPINCOTT WILLIAMS & WILKINS.

19. **Kachakova D**, Mitkova A, Popov E, Beltcheva O, Vlahova A, Dikov T, Christova S, Mitev V, Slavov C, Kaneva R. Polymorphisms in androgen metabolism genes AR, CYP1B1, CYP19, and SRD5A2and prostate cancer risk and aggressiveness in Bulgarian patients. Turk J Med Sci. 2016 Apr 19;46(3):626-40. doi: 10.3906/sag-1501-124. IF 2016 (0.710)

20. Stegeman S, Amankwah E, Klein K, O'Mara TA, Kim D, Lin HY, Permuth-Wey J, Sellers TA, Srinivasan S, Eeles R, Easton D, Kote-Jarai Z, Amin Al Olama A, Benlloch S, Muir K, Giles GG, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Neal D, Pharoah P, Khaw KT, Stanford JL, Blot WJ, Thibodeau S, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Kaneva R, Teixeira MR; **PRACTICAL** Consortium.; Australian Prostate Cancer BioResource., Spurdle AB, Clements JA, Park JY, Batra J. A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer. Cancer Discov. 2015 Apr;5(4):368-79. doi: 10.1158/2159-8290.CD-14-1057. IF 2015 (19.783)

21. Amin Al Olama A, Benlloch S, Antoniou AC, Giles GG, Severi G, Neal DE, Hamdy FC, Donovan JL, Muir K, Schleutker J, Henderson BE, Haiman CA, Schumacher FR, Pashayan N, Pharoah PD, Ostrander EA, Stanford JL, Batra J, Clements JA, Chambers SK, Weischer M, Nordestgaard BG, Ingles SA, Sorensen KD, Orntoft TF, Park JY, Cybulski C, Maier C, Doerk T, Dickinson JL, Cannon-Albright L, Brenner H, Rebbeck TR, Zeigler-Johnson C, Habuchi T, Thibodeau SN, Cooney KA, Chappuis PO, Hutter P, Kaneva RP, Foulkes WD, Zeegers MP, Lu YJ, Zhang HW, Stephenson R, Cox A, Southey MC, Spurdle AB, FitzGerald L, Leongamornlert D, Saunders E, Tymrakiewicz M, Guy M, Dadaev T, Little SJ, Govindasami K, Sawyer E, Wilkinson R, Herkommer K, Hopper JL, Lophatonanon A, Rinckleb AE, Kote-Jarai Z, Eeles RA, Easton DF; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators; **PRACTICAL** Consortium. Risk Analysis of Prostate Cancer in **PRACTICAL**, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. Cancer Epidemiol Biomarkers Prev. 2015 Jul;24(7):1121-9. doi: 10.1158/1055-9965.EPI-14-0317. Epub 2015 Apr 2. IF 2015 (3.622)

21. Gusev A, Shi H, Kichaev G, Pomerantz M, Li F, Long HW, Ingles SA, Kittles RA, Strom SS, Rybicki BA, Nemesure B, Isaacs WB, Zheng W, Pettaway CA, Yeboah ED, Tettey Y, Biritwum RB, Adjei AA, Tay E, Truelove A, Niwa S, Chokkalingam AP, John EM, Murphy AB, Signorello LB, Carpten J, Leske MC, Wu SY, Hennis AJ, Neslund-Dudas C, Hsing AW, Chu L, Goodman PJ, Klein EA, Witte JS, Casey G, Kaggwa S, Cook MB, Stram DO, Blot WJ, Eeles RA, Easton D, Kote-Jarai Z, Al Olama AA, Benlloch S, Muir K, Giles GG, Southey MC, Fitzgerald LM, Gronberg H, Wiklund F, Aly M, Henderson BE, Schleutker J, Wahlfors T, Tammela TL, Nordestgaard BG, Key TJ, Travis RC, Neal DE, Donovan JL, Hamdy FC, Pharoah P, Pashayan N, Khaw KT, Stanford JL, Thibodeau SN, McDonnell SK, Schaid DJ, Maier C, Vogel W, Luedeke M, Herkommer K, Kibel AS, Cybulski C, Wokolorczyk D, Kluzniak W, Cannon-Albright L, Teerlink C, Brenner H, Dieffenbach AK, Arndt V, Park JY, Sellers TA, Lin HY, Slavov C, Kaneva R, Mitev V, Batra J, Spurdle A, Clements JA, Teixeira MR, Pandha H, Michael A, Paulo P, Maia S, Kierzek A; **PRACTICAL** consortium., Conti DV, Albanes D, Berg C, Berndt SI, Campa D, Crawford ED, Diver WR, Gapstur SM, Gaziano JM, Giovannucci E, Hoover R, Hunter DJ, Johansson M, Kraft P, Le Marchand L, Lindström S, Navarro C, Overvad K, Riboli E, Siddiq A, Stevens VL, Trichopoulos D, Vineis P, Yeager M, Trynka G, Raychaudhuri S, Schumacher FR, Price AL, Freedman ML, Haiman CA, Pasaniuc B. Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. Nat Commun. 2016 Apr 7;7:10979. doi: 10.1038/ncomms10979. IF 2016 (12.124)

22. Davies NM, Gaunt TR, Lewis SJ, Holly J, Donovan JL, Hamdy FC, Kemp JP, Eeles R, Easton D, Kote-Jarai Z, Al Olama AA, Benlloch S, Muir K, Giles GG, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Neal D, Pashayan N, Khaw KT, Stanford JL, Blot WJ, Thibodeau S, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Park J, Kaneva R, Batra J, Teixeira MR, Pandha H; **PRACTICAL** consortium., Lathrop M, Smith GD, Martin RM. The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium. Cancer Causes Control. 2015 Nov;26(11):1603-16. doi: 10.1007/s10552-015-0654-9. IF 2015 (2.735)

23. Szulkin R, Whitington T, Eklund M, Aly M, Eeles RA, Easton D, Kote-Jarai ZS, Amin Al Olama A, Benlloch S, Muir K, Giles GG, Southey MC, Fitzgerald LM, Henderson BE, Schumacher F, Haiman CA, Schleutker J, Wahlfors T, Tammela TL, Nordestgaard BG, Key TJ, Travis RC, Neal DE, Donovan JL, Hamdy FC, Pharoah P, Pashayan N, Khaw KT, Stanford JL, Thibodeau SN, McDonnell SK, Schaid DJ, Maier C, Vogel W, Luedeke M, Herkommer K, Kibel AS, Cybulski C, Lubiński J, Kluźniak W, Cannon-Albright L, Brenner H, Butterbach K, Stegmaier C, Park JY, Sellers T, Lin HY, Slavov C, Kaneva R, Mitev V, Batra J, Clements JA; Australian Prostate Cancer BioResource., Spurdle A, Teixeira MR, Paulo P, Maia S, Pandha H, Michael A, Kierzek A; Practical Consortium., Gronberg H, Wiklund F. Prediction of individual genetic risk to prostate cancer using a polygenic score. Prostate. 2015 Sep;75(13):1467-74. doi: 10.1002/pros.23037. Erratum in: Prostate. 2015 Dec;75(16):1972. Lim, Hui-Yi [corrected to Lin, Hui-Yi]. IF 2015 (3.778)

24. Amin Al Olama A, Dadaev T, Hazelett DJ, Li Q, Leongamornlert D, Saunders EJ, Stephens S, Cieza-Borrella C, Whitmore I, Benlloch Garcia S, Giles GG, Southey MC, Fitzgerald L, Gronberg H, Wiklund F, Aly M, Henderson BE, Schumacher F, Haiman CA, Schleutker J, Wahlfors T, Tammela TL, Nordestgaard BG, Key TJ, Travis RC, Neal DE, Donovan JL, Hamdy FC, Pharoah P, Pashayan N, Khaw KT, Stanford JL, Thibodeau SN, Mcdonnell SK, Schaid DJ, Maier C, Vogel W, Luedeke M, Herkommer K, Kibel AS, Cybulski C, Wokołorczyk D, Kluzniak W, Cannon-Albright L, Brenner H, Butterbach K, Arndt V, Park JY, Sellers T, Lin HY, Slavov C, Kaneva R, Mitev V, Batra J, Clements JA, Spurdle A, Teixeira MR, Paulo P, Maia S, Pandha H, Michael A, Kierzek A, Govindasami K, Guy M, Lophatonanon A, Muir K, Viñuela A, Brown AA; **PRACTICAL** Consortium.; COGS-CRUK GWAS-ELLIPSE (Part of GAME-ON) Initiative.; Australian Prostate Cancer BioResource.; UK Genetic Prostate Cancer Study Collaborators.; UK ProtecT Study Collaborators., Freedman M, Conti DV, Easton D, Coetzee GA, Eeles RA, Kote-Jarai Z. Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. Hum Mol Genet. 2015 Oct 1;24(19):5589-602. doi: 10.1093/hmg/ddv203. IF 2015 (5.985)

25. Bonilla C, Lewis SJ, Martin RM, Donovan JL, Hamdy FC, Neal DE, Eeles R, Easton D, Kote-Jarai Z, Al Olama AA, Benlloch S, Muir K, Giles GG, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Pashayan N, Khaw KT, Stanford JL, Blot WJ, Thibodeau S, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Park J, Kaneva R, Batra J, Teixeira MR4, Pandha H, Lathrop M, Davey Smith G; **PRACTICAL** consortium. Pubertal development and prostate cancer risk: Mendelian randomization study in a population-based cohort. BMC Med. 2016 Apr 4;14:66. doi: 10.1186/s12916-016-0602-x. IF 2016 (8.097)

26. Lophatananon A, Stewart-Brown S, Kote-Jarai Z, Olama AAA, Garcia SB, Neal DE, Hamdy FC, Donovan JL, Giles GG, Fitzgerald LM, Southey MC, Pharoah P, Pashayan N, Gronberg H, Wiklund F, Aly M, Stanford JL, Brenner H, Dieffenbach AK, Arndt V, Park JY, Lin HY, Sellers T, Slavov C, Kaneva R, Mitev V, Batra J, Spurdle A, Clements JA; APCB BioResource; **PRACTICAL** consortium, Easton D, Eeles RA, Muir K. Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium. Br J Cancer. 2017 Aug 22;117(5):734-743. doi: 10.1038/bjc.2017.231. Epub 2017 Aug 1. Erratum in: Br J Cancer. 2018 Feb 13; IF 2016 (6.176)

27. Hadzhiev Y, Yordanov S, Popova D, Kachakova D. BPIFA1 Gene Expression in the Human Middle Ear Mucosa. J Int Adv Otol. 2017 Dec;13(3):340-344. doi: 10.5152/iao.2017.4305.

28. Dora Marinova, **Darina Kachakova**, Atanaska Mitkova, Gergana Stancheva, Yanina Slavova, Denitsa Dimitrova, Evgeni Mekov, Aleksandar Lilov, Miroslav Mihailov, Dimitar Kostadinov, Radka Kaneva, Vanio Mitev. Expression analysis of miR-21 in Bulgarian patients with non-small cell lung cancer. European Respiratory Journal 2016 48: PA2854; DOI: 10.1183/13993003.congress-2016.PA2854

29. Rangelov, I. I., Parvanov, D. A., Stamenov, G. S., Tzankova, G. I., Kaneva, R. P., Kachakova, D. L., & Chaushev, T. A. (2017). Micrornas in blastocyst culture medium as noninvasive biomarkers for assessing the implantation potential of human embryos. Fertility and Sterility, 108(3), e83.

30. Shumnalieva R, **Kachakova D**, Monov S, et al 02.46 Microrna-146a and disease activity in sle patients Annals of the Rheumatic Diseases 2017;76:A27-A28.

31. D Marinova, **D Kachakova**, Y Slavova, G Stancheva, Mitkova A. Kaneva R, Kostadinov D, Mitev V. RT-PCR expression of EML4-ALK oncogene in Bulgarian patients with non-small cell lung cancers. European Respiratory Journal 2015 46: PA4254; DOI: 10.1183/13993003.congress-2015.PA4254

32. Shumnalieva R, **Kachakova D**, Monov S, et al 317 Dysregulation of mirnas expression levels and disease activity in sle patients Lupus Science & Medicine 2017;4:doi: 10.1136/lupus-2017-000215.317

33. Shumnalieva R, **Kachakova D**, Monov S, et al THU0023 Synovial fluid mirnas multimarker analysis in patients with rheumatoid arthritis Annals of the Rheumatic Diseases 2017;76:208.

34. Shumnalieva R, Velikova T, **Kachakova D**, et al 03.07 Serum and synovial concentration of il-17a in rheumatoid arthritis patients Annals of the Rheumatic Diseases 2017;76:A32.

35. Dadaev T, Saunders EJ, Newcombe PJ, Anokian E, Leongamornlert DA, Brook MN, Cieza-Borrella C, Mijuskovic M, Wakerell S, Olama AAA, Schumacher FR, Berndt SI, Benlloch S, Ahmed M, Goh C, Sheng X, Zhang Z, Muir K, Govindasami K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman P, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger G, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Hakansson N, West C, Dunning AM, Burnet N, Mucci L, Giovannucci E, Andriole G, Cussenot O, Cancel-Tassin G, Koutros S, Freeman LEB, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein B, Kerns S, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Fachal L, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weisher M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Slavov C, Mitev V, Parliament M, Singhal S, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Kierzek A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Kraft P; **PRACTICAL** (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, Freedman M, Wiklund F, Chanock S, Henderson BE, Easton DF, Haiman CA, Eeles RA, Conti DV, Kote-Jarai Z. Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nat Commun. 2018 Jun 11;9(1):2256. doi: 10.1038/s41467-018-04109-8. PMID: 29892050

36. Shumnalieva R, **Kachakova D**, Shoumnalieva-Ivanova V, Miteva P, Kaneva R, Monov S. Whole peripheral blood miR-146a and miR-155 expression levels in Systemic lupus erythematosus patients. Acta Reumatol Port. 2018 Jul-Sep;43(3):217-225. PMID: 30414370

37. Matejcic M, Saunders EJ, Dadaev T, Brook MN, Wang K, Sheng X, Olama AAA, Schumacher FR, Ingles SA, Govindasami K, Benlloch S, Berndt SI, Albanes D, Koutros S, Muir K, Stevens VL, Gapstur SM, Tangen CM, Batra J, Clements J, Gronberg H, Pashayan N, Schleutker J, Wolk A, West C, Mucci L, Kraft P, Cancel-Tassin G, Sorensen KD, Maehle L, Grindedal EM, Strom SS, Neal DE, Hamdy FC, Donovan JL, Travis RC, Hamilton RJ, Rosenstein B, Lu YJ, Giles GG, Kibel AS, Vega A, Bensen JT, Kogevinas M, Penney KL, Park JY, Stanford JL, Cybulski C, Nordestgaard BG, Brenner H, Maier C, Kim J, Teixeira MR, Neuhausen SL, De Ruyck K, Razack A, Newcomb LF, Lessel D, Kaneva R, Usmani N, Claessens F, Townsend PA, Gago-Dominguez M, Roobol MJ, Menegaux F, Khaw KT, Cannon-Albright LA, Pandha H, Thibodeau SN, Schaid DJ; **PRACTICAL** Consortium, Wiklund F, Chanock SJ, Easton DF, Eeles RA, Kote-Jarai Z, Conti DV, Haiman CA. Author Correction: Germline variation at 8q24 and prostate cancer risk in men of European ancestry. Nat Commun. 2019 Jan 17;10(1):382. doi: 10.1038/s41467-019-08293-z. PMID: 30655571